Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Overall survival · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel showed no clear difference in overall survival compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.97 [0.77, 1.23]
1 study · 330 participants
Low